
[Cancer Research 54, 2650-2653, May 15, 1994]
© 1994 American Association for Cancer Research
Effects of Sonicated Eosinophils on the in Vitro Sensitivity of Human Lymphoma Cells to Glucose Oxidase1
Michael K. Samoszuk2,
Vincent Nguyen,
Cherry T. Thomas and
Dawn M. Jacobson
Pathology Department, University of California, Irvine, California 92717
We report here that cultured human lymphoma cells in the absence of sonicated eosinophils are sensitive to killing by glucose oxidase (ß-D-glucose:oxygen-oxido reductase; EC 1.1.3.4) at concentrations as low as 0.025 µg/ml, a level that can be rapidly attained in s.c. tumor implants in mice that receive a single nonlethal injection of enzyme. Multiple clonogenic assays were used to measure the survival of human lymphoma cell lines (H9 and ARH-77) cultured for 14 days in complete RPMI 1640 supplemented with exogenous glucose oxidase (0.0252.5 µg/ml) or an immunoconjugate containing glucose oxidase (0.2525 µg/ml) in the presence or absence of catalase (10 µg/ml) or an equal number of sonicated human eosinophils with or without supplemental 100 µM Br-, I-, or SCN-. In addition, we used an immunoassay to measure the concentration of glucose oxidase in s.c. implants of the Sp 2/0 myeloma tumor at 030 min after an i.v. injection of 50 µg of enzyme into 21 BALB/c mice. Doses of glucose oxidase as small as 0.025 µg/ml killed more than 3 logs of tumor cells. Catalase completely inhibited, and sonicated human eosinophils partially inhibited, the killing by glucose oxidase or immunoconjugate, whereas supplemental halides had no effect. Glucose oxidase i.v. produced levels >0.04 µg/g of tumor for 30 min after injection with a peak concentration of 0.079 µg/g of tumor within 5 min of injection. These results are important because certain human lymphomas contain extensive extracellular deposits of eosinophil peroxidase, thereby making these tumors potentially less susceptible to killing by otherwise therapeutic doses of glucose oxidase.
1 This work was supported by USPHS Grant NIH R29 CA 48713.
2 To whom requests for reprints should be addressed, at Medical Sciences D-440, Pathology Department, University of California, Irvine, CA 92717.
Received 1/12/94.
Accepted 3/16/94.
This article has been cited by other articles:

|
 |

|
 |
 
J. C. MacPherson, S. A. A. Comhair, S. C. Erzurum, D. F. Klein, M. F. Lipscomb, M. S. Kavuru, M. K. Samoszuk, and S. L. Hazen
Eosinophils Are a Major Source of Nitric Oxide-Derived Oxidants in Severe Asthma: Characterization of Pathways Available to Eosinophils for Generating Reactive Nitrogen Species
J. Immunol.,
May 1, 2001;
166(9):
5763 - 5772.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1994 by the American Association for Cancer Research.